Fanconi anemia (FA) is a rare genetically heterogeneous disorder associated with bone marrow failure, birth defects and cancer susceptibility. Apart from the diseasecausing mutations in FANC genes, the identification of specific DNA variations, such as single nucleotide polymorphisms (SNPs), in other candidate genes may lead to a better clinical description of this condition enabling individualized treatment with improvement of the prognosis. In this study, we have assessed 95 SNPs located in 52 key genes involved in base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), double strand break (DSB) repair and cell cycle control using a DNA repair chip (Asper Biotech, Estonia) which includes most of the common variants for the candidate genes. The SNP genotyping was performed in five FA-D2 patients and in one FA-A patient. The polymorphisms studied were synonymous (n=10), nonsynonymous (missense) (n=52) and in non-coding regions of the genome (introns and 5 'and 3' untranslated regions (UTR)) (n=33). Polymorphisms found at the homozygous state are selected for further analysis. Our results have shown a significant inter-individual variability among patients in the type and the frequency of SNPs and also elucidate the need for further studies of polymorphisms located in ATM, APEX APE 1, XRCC1, ERCC2, MSH3, PARP4, NBS1, BARD1, CDKN1B, TP53 and TP53BP1 696 GENETIKA, Vol. 47, No.2,695-710, 2015 which may be of great importance for better clinical description of FA. In addition, the present report recommends the use of SNPs as predictive and prognostic genetic markers to individualize therapy of FA patients. Key words: DNA repair, Fanconi anemia, single nucleotide polymorphisms List of abbreviations APEX APE1-APEX nuclease (multifunctional DNA repair enzyme) 1; ATM-ataxia telangiectasia mutated serine/threonine kinase; BRCA1-breast cancer 1, early onset; BARD1-BRCA1 associated RING domain 1; BRCA2-breast cancer 2, early onset; BER-base excision repair; CCND1-cyclin D1; CCNH-cyclin H; p21/CDKN1A-cyclin-dependent kinase inhibitor 1A (p21, Cip1); CDKN2A-cyclin-dependent kinase inhibitor 2A ; CDKN1B-cyclin-dependent kinase inhibitor 1B (p27, Kip1); CDK7-cyclin-dependent kinase 7; CHEK2-checkpoint kinase 2; DSB-double strand break; ERCC1-excision repair cross-complementation group 1; ERCC2-excision repair cross-complementation group 2; ERCC4-excision repair cross-complementation group 4; ERCC5-excision repair cross-complementation group 5; FANCD2-Fanconi anemia, complementation group D2; GADD45A-growth arrest and DNA-damage-inducible, alpha; GRTH/Ddx25-DEAD (Asp-Glu-Ala-Asp) box helicase 25; LIG1-ligase I, DNA, ATP-
INTRODUCTION
Fanconi anemia (FA) is a recessive disorder considered to encompass a defect in maintenance of genome integrity. It is associated with bone marrow failure, birth defects and predisposition to cancer. The disease is genetically heterogeneous with 16 complementation groups (FA -A to FA -Q) and associated genes having been characterized (KEE and D'ANDREA, 2012; BOGLIOLO et al., 2013; CHEN et al., 2014) . All of the 16 gene products operate in a common process to maintain genome stability. Some of these proteins have extranuclear activities affecting redox balance, apoptosis and energy metabolism (CAPPELLI et al., 2013) . The most frequent complementation group is FA-A (~ 60% of all cases of the disease); FA-C and FA-G account for ~ 10-15% of the cases while the rest of the cases (~ 15%) is distributed over the remaining complementation groups (e.g. the prevalence of FA-D2 is 3.3%) (MAGDALENA et al., 2005; MATHEW, 2006; AMEZIANE et al., 2012) . Regardless of the complementation group, FA is a condition involving high risk of leukemia and solid tumors (KUTLER et al., 2003) . However, FA patients exhibit a high degree of clinical variability and have poor tolerance for radiotherapy and chemotherapy (MATHEW, 2006) . Thus, the knowledge of factors that might predict either the best drug response or adverse outcome would greatly facilitate the decision making concerning the choices of treatment.
Single nucleotide polymorphisms (SNPs) represent one of the largest types of inherited genetic variations (BOND and LEVINE, 2007) and are considered as predictive and prognostic genetic markers. Polymorphisms in DNA repair and cell cycle control genes may alter protein function leading to genomic instability and increased cancer risk (SIGURDSON et al., 2004) .
As already known, Fanconi anemia is a disease associated with deficiencies in DNA repair pathway, which may be the cause of the overall increased cancer risk in patients. FA proteins constitute the FA pathway responsible for repair of inter -and intra -strand DNA crosslinks either occurring spontaneously or induced by clastogens as mitomycin C or diepoxybutane (JOENJE and PATEL, 2001 ; KIM and D'ANDREA, 2012) . However, apart from the disease-causing mutations in FANC genes, the identification of specific variations in other candidate genes in FA patients may lead to a better clinical description of this condition enabling individualized treatment with improvement of the prognosis. In light of the fact that Fanconi anemia is a highly penetrant cancer susceptibility disorder, the products of the identified genes could become targets for innovative therapies in patients. In addition, the genotyping of SNPs in key genes involved in DNA repair may provide insight into the interactions between FA mutation and specific variations in DNA repair genes in each of the FA patients.
The results presented here focus on assessment of the known variations located in genes involved in base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), double strand break (DSB) repair and also in the several genes related to the cell cycle control and apoptosis. Investigation was performed in patients belonging to complementation groups FA-A and FA-D2; the last one present as the most prevalent complementation group in Serbia.
MATERIALS AND METHODS

Patients
Six patients aged 3 to 13 years who had previously been diagnosed with FA based on clinical features were enrolled in this study. All of the patients had several developmental malformations (skin, skeletal, genitourinary and neurological anomalies) and developed bone marrow failure at an early age. At the moment of sampling, no one of the patients has been diagnosed with cancer. A clinical diagnosis of FA was confirmed by a positive diepoxybutane (DEB) test (AUERBACH, 1993) . Complementation group assignment was performed by immunoblotting at the Department of Genetics Microbiology, Universitat Autonoma de Barcelona, Spain, and at Universität Würzburg, Institut für Humangenetik, Germany. The FA complementation group analysis showed that five patients belong to the complementation group FA-D2 (Patients #1 -#5), whereas only one patient belongs to the complementation group FA-A (Patient #6). Informed consent for investigation was obtained from all families, and the study was approved by the Ethical Committee of the Mother and Child Health Care Institute of Serbia.
DNA isolation
DNA was isolated from patients-derived fibroblasts using the phenol-chloroform method. The cells were treated with STE buffer (10 mM TRIS-HCl, 100 mM NaCl, 1 mM EDTA), proteinase K (10 mg/mL) (Sigma-Aldrich) and 10% SDS (sodium dodecyl sulfate) (Sigma-Aldrich) and incubated for 2 hours at 55 ºC. Afterwards, the upper layer (250 -300 µL) was transferred to a new tube, and dH 2 O (50 µL) and phenol (Sigma-Aldrich) (300 µL) were added. The suspension was vigorously vortexed and then centrifuged for 10 minutes at 12000 rpm in a microcentrifuge. The supernatant (250 -300 µL) was placed into a new tube and chloroform (~150 µL) (SigmaAldrich) was added. After centrifugation for 10 minutes at 12000 rpm, the supernatant (250 -300 µL) was transferred to a new tube and treated with 7.5 M ammonium acetate (150 µL) and icecold 100% ethanol (1.5 mL). After centrifugation for 5 minutes at 12000 rpm, the supernatant was decanted and the pellet was air-dried for 1-2 minutes and re-suspended in appropriate volume dH 2 O (30-50 µL). The quantification of the concentration and purity of the DNA was performed using a spectrophotometer (Nanodrop-1000, Thermo Fisher Scientific, USA).
Single nucleotide polymorphism analysis
For SNP analysis, DNA samples (concentration 1 µg/µL at least) were studied using DNA repair chip which includes most of the common variants for the DNA repair genes as well as for the several genes related to the cell cycle control and apoptosis. The SNP genotyping was performed at the Asper Biotech (Tartu, Estonia) (http://www.asperbio.com/DNArepairchip.pdf). The total number of SNPs analyzed in this cohort is 95, and the total number of genes is 52.
RESULTS
In this study, we have assessed 95 SNPs located in 52 key genes involved in BER, NER, MMR, DSB repair and cell cycle control using an Asper Biotech array. The investigation was performed in five FA-D2 patients and in one FA-A patient. The summary of genes involved in different repair and cell cycle control pathways and corresponding SNPs are presented in Tables 1  -2 . Some genes are involved in more than one pathway, but each is listed only once. All of the SNPs studied are accessible at the NCBI (National Center for Biotechnology Information) database (http://www.ncbi.nlm.nih.gov/snp).
The polymorphisms studied were synonymous (n=10), nonsynonymous (missense) (n=52) and in non-coding regions of the genome (introns and 5 'and 3' untranslated regions (UTR)) (n=33). Polymorphisms found at the homozygous state (genotypes in bold, see Tables 1-2) are selected for further analysis.
In the BER pathway, the SNPs located in APEX, LIG1, LIG3, MYH, OGG1, PARP1, PCNA, POLB and XRCC1 were evaluated. As shown in Table 1 , the most of the studied polymorphisms were found as heterozygous variants, while the homozygous variants were found in APEX APE1, LIG1, LIG3 and PARP1. The missense variation was found in APEX APE1 (rs3136820) (p.Asp148Glu) in patients #2 and #5. In LIG1, an intronic variation (rs3730849) was found in patients #3 and #5, while the intronic rs1805403 of PARP1 was detected in patients #3, #4 and #6. The 3`-UTR rs1052536 of LIG3 was found in patients #5 and #6.
In the NER pathway, we analyzed polymorphisms located in ERCC1, ERCC2 (XPD), ERCC4 (FANCQ), ERCC5 (XPG), GADD45A, RAD23B, XPA and XPC (Table 1 ). The homozygous missense variation rs13181 (p.Lys751Gln) of ERCC2 was found in patient #3. The intronic rs3212948 of ERCC1 was detected in patients #1, #2, #4 and #5. In GADD45A, an intronic rs532446 was detected in patients #1 and #2, while the 5`-UTR variant rs1800975 of XPA was detected in patients #1, #2 and #5. Base excision repair (BER) 
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In the MMR pathway, the SNPs located in MLH1, MSH2, MSH3, MSH6, PMS2 and RECQL were evaluated. The homozygous missense variants rs184967 (p.Gln949Arg) and rs26279 (p.Ala1045Thr) of MSH3 were found in patients #2 and #5, and patient #5, respectively. The synonymous rs1800935 of MSH6 was detected in patient #6.
In the DSB repair pathway, which consists of both homologous recombination and nonhomologous end-joining, SNPs located in BRCA1, BRCA2 (FANCD1), FANCD2, LIG4, NBS1, PARP4, RAD51, RAD52, RAD54B, XRCC2, XRCC3, XRCC4, XRCC5 and XRCC9 (FANCG) were investigated (Table 1) . Similar to the results obtained analyzing the BER, NER and MMR pathways explained above, the most of the nucleotide changes were at the heterozygous state. The Exon 22
homozygous variants were found in BARD 1, NBS1, PARP4, RAD54B, RAD52, FANCD2 and XRCC4. The missense rs2070094 (p.Val507Met) of BARD 1 was detected in patients #1 and #6. The rs1805794 (p.Glu185Gln) of NBS1 was detected in patient #4. The rs1050112 (p.Pro1328Thr) and rs13428 (p.Gly1280Arg) of PARP4 were found in patient #5. The same patient also carried the rs7571 (p.Ala1656Pro) located in the same gene. Of the synonymous polymorphisms investigated, the rs2070093 of BARD1 was found in patients #1, #2, #3 and #6. The rs1063045 of NBS1 was found in patient #4, while the rs2291439 of RAD54B was found in patient #1. Considering the polymorphisms located in the non-coding regions, the 5`-UTR rs1799943 of BRCA2 was found in patient #2. The 5`-UTR rs3732974 located in FANCD2 was found in all of the patients. The 3`-UTR rs11226 located in RAD52 was found in patient #4. The intronic rs1799796 of XRCC3 was found in patient #5, while the intronic rs1805377 of XRCC4 was found in patient #3. Results of the analysis of SNPs located in the genes involved in cell cycle control and apoptosis are presented in Table 2 . We assessed polymorphisms located in ATM, CCND1, CCNH, p21/CDKN1A, CDKN2A, CDKN1B, CDK7, CHEK2, GRTH/Ddx25, RAD9A, TP53, TP53BP1 and TP53BP2. The homozygous variants were found in ATM, CDKN1B, TP53, TP53BP1, CCND1 and GRTH/Ddx25. The missense polymorphism rs34330 (p.Leu332Pro) of CDKN1B was detected in patients #2 and #6. The rs1042522 (p.Pro72Arg) of TP53 was found in patients #4 and #5. The rs560191 (p.Asp353Glu) of TP53BP1 was found in patient #3. The synonymous rs603965 located in CCND1 was detected in patient #3, while the rs683155 of GRTH/Ddx25 was found in patients #1 and #6. In addition, the intronic variant rs664677 of ATM was identified in patient #5, while the 3`-UTR rs678653 located in CCND1 was found in patients #1 and #3.
Considering the missense nucleotide substitutions in all of the studied genes, we have observed that among the 52 analyzed SNPs, the 29 (~56%) were identified in our patients as heterozygous variants, while the 12 of them (~23%) were detected as homozygous variants. Of the 10 synonymous SNPs, the six (60%) were found in our patients at the homozygous state. In 
view of the 33 SNPs located in the non-coding regions of selected genes, the thirteen (~40%) of them were identified in some of our patients as homozygous variants. Summarizing the results presented above it could be seen that SNPs identified at the homozygous state were not equally distributed among the patients. Patient #1 carried one missense, three synonymous and five polymorphisms in the non-coding region of the genes. Patient #2 carried three missense, one synonymous and five substitutions in the non-coding regions. Patient #3 carried two missense, two synonymous and five substitutions in the noncoding regions of the genes. Patient #4 carried two missense, one synonymous and four polymorphisms in the non-coding regions. Patient #5 carried seven missense variations, seven variations in the non-coding regions of the genes and no one homozygous synonymous substitution. Finally, patient #6 carried two missense variations, three synonymous and three variations in the non-coding regions of selected genes.
Taken together, the results of our investigation have shown a significant inter-individual variability among patients in the type and the frequency of SNPs.
Extensive analysis of the genotype-phenotype correlations in this cohort was not possible because of the small number of patients.
DISCUSSION
This study was aimed at defining the factors that might influence a DNA repair capacity in FA patients, which may allow for a more rational therapeutic approach. Accumulating evidence suggests that reduced repair capacity is a polymorphic phenotypic trait associated with an increased risk of developing tumors at several sites, including breast, lung, skin, liver, or head/neck (BERWICK and VINEIS, 2000; MOHRENWEISER et al., 2002) . Therefore, the data of the factors of the integrity of DNA repair pathways may be used not only in the development of novel therapeutic agents but also for the understanding of the high degree of phenotypic and clinical heterogeneity in Fanconi anemia which is in evident contrast with the uniform cellular phenotype (HODSON and WALDEN, 2013) .
In this study, we have genotyped the known polymorphisms located in the DNA repair and cell cycle control genes in FA patients and observed that most of the polymorphisms are present at the heterozygous state. Considering the polymorphisms with functional consequences i.e., missense polymorphisms, it is possible that heterozygous nucleotide changes in the genes of interest could also have various biological and/or pathophysiological effects on FA patients. Recent report of Alsbeih and coworkers (ALSBEIH et al., 2013) has shown that radiation toxicity in radiotherapy patients is associated with polymorphisms rs1801516 of ATM and rs25487 of XRCC1. Results of that study suggest that the presence of protective alleles (ATM rs1801516 A and XRCC1 rs25487 A) at the heterozygous status would increase patients' follow-up after radiotherapy by 51 months, while homozygous status would raise this index by 77 months. In our cohort, all of the FA-D2 patients were homozygote carriers of the ATM G allele. These results are in concordance with our previous investigations reporting the marked radiosensitivity of FA patients (LESKOVAC et al., 2010; JOKSIC et al., 2012; LESKOVAC et al., 2014) and support the use of SNPs in candidate genes as predictive markers of patients' radiosensitivity.
In the BER pathway, the homozygous missense nucleotide changes (rs3136820) were found in the APEX. This endonuclease recognizes and begins the process of removing abasic sites in DNA (WILSON and THOMPSON, 1997) . It has been reported that 148Glu polymorphism does not reduce endonuclease activity but it is associated with increased mitotic delay after exposure to ionizing radiation and an increased risk of colorectal cancer (HU et al., 2001; KASAHARA et al., 2008) . Our previous investigations have shown that exposure to ionizing radiation in vitro significantly slowed down the proliferation of FANCD2 fibroblasts compared to control fibroblasts (JOKSIC et al., 2012; LESKOVAC et al., 2014) .
In the NER pathway, we detected the homozygous missense polymorphism rs13181 (p.Lys751Gln) of ERCC2 which is associated with a risk of acute myeloid leukemia, melanoma, chronic lymphocytic leukemia and squamous head and neck cancer (CHANG-CLAUDE et al., 2009; GANSTER et al., 2009; MITRA et al., 2009; STROM et al., 2010) . Of the two homozygous missense polymorphisms located in MSH3 (MMR pathway), the rs26279 is associated with increased sensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer patients (XU et al., 2015) .
In the DSB repair pathway, the homozygous missense variations were found in BARD 1, NBS1, and PARP4. The rs1805794 (p.Glu185Gln) of NBS1 is associated with increased risk for urinary system cancer, especially for bladder cancer , while the functional consequences of the rs1050112 (p.Pro1328Thr), rs13428 (p.Gly1280Arg) and rs7571 of PARP4 as well as of the rs2070094 (p.Val507Met) of BARD1 are still unknown. The significance of these findings is not known yet but may be important for future testing and improvement of the diagnosis and outcomes in patients with FA.
Considering the genes involved in the cell cycle control and apoptosis, the homozygous missense variations were found in CDKN1B, TP53 and TP53BP1. The p53 protein is essential for regulating different cellular processes such as DNA repair, cell cycle arrest and apoptosis and therefore, has a crucial role in maintaining the genetic integrity of the cells (RILEY et al., 2008) . The functional SNPs located in TP53 are confirmed to affect the p53 signaling pathway (GROCHOLA et al., 2010) . The rs1042522 (p.Pro72Arg) of TP53 at homozygous state was found in two of our patients, while the rest of them were heterozygotes. It has been shown that 72Arg variant has a stronger ability to induce apoptosis then 72Pro variant. In other words, 72Arg is more efficiently translocated to the mitochondria, where it interacts with proapoptotic proteins such as GRP75 and Hsp60, consequently triggering apoptosis (DUMONT et al., 2003) . These results are in accordance with our previous investigation of FA patients describing the elevated level of leukocyte apoptosis either occurring spontaneously or induced by ionizing radiation . Additionally, the report of Litviakov and coworkers (LITVIAKOV et al., 2010) has shown that 72Arg variant is coupled with higher frequency of aberrant cells and chromatid breaks in comparison to individuals with Pro/Pro genotypes. This polymorphism is also associated with high risk of diabetes II and acute lymphoblast leukemia (GAULTON et al., 2008; DO et al., 2009) . As for the other two found polymorphisms, the rs34330 of CDKN1B is reported to have an association with breast cancer (DRIVER et al., 2008) , while the rs560191 (p.Asp353Glu) of TP53BP1 is associated with a risk of lung cancer (TRUONG et al., 2010) . As previously stated, the homozygous synonymous nucleotide changes were found in BARD1, MSH6, NBS1, RAD54B, CCND1 and GRTH/Ddx25 . The literature data provide the evidence that synonymous mutations are "silent" with respect to protein sequence but are not always "silent" regarding protein function (GINGOLD and PILPEL, 2011) . Synonymous SNPs could influence protein function affecting mRNA secondary structure and stability consequently reducing protein expression (NACKLEY et al., 2006) . In other words, "silent" changes may possibly affect the mRNA translation (DRUMMOND and WILKE, 2008) , folding (GOODMAN et al., 2013) and splicing (PARMLEY et al., 2006) , or, through translational pausing, a protein folding . Silent mutations are proven to contribute to human cancer (SUPEK et al., 2014) .
In this study, the thirteen homozygous variants were found in the non-coding regions of the genes tested. Several studies provided evidence that SNPs located in the non-coding DNA, especially in intronic gene regions near the exon/intron boundaries, could inactivate pre-mRNA splice sites consequently affecting gene expression (LOMELIN et al., 2010; VOGELSTEIN et al., 2013) , or could activate cryptic splice sites leading to exonization (WANG and COOPER, 2007) . Furthermore, the presence of SNPs in the 3`-UTR of selected genes could modify the binding with specific microRNAs (miRNAs) (NACCARATI et al., 2012) . It has been reported that one of the key mechanisms of gene expression control is a post-transcriptional gene regulation by miRNAs which interact with the 3`-UTR of target mRNAs inducing their degradation or inhibition of their translation, thus silencing gene expression (BARTEK and LUKAS, 2007; FILIPOWICZ et al., 2008) . Therefore, the SNPs could alter the miRNA-mRNA interaction consequently inducing the increase or decrease of protein translation (DUAN et al., 2009) . In addition, the sequence changes in the 5´ -UTR regions of mRNAs can influence translation regulation (WARD and KELLIS, 2012). There are many association studies providing the linkage between SNPs in non-coding regions of candidate genes and cancer propensity. As for the homozygous polymorphisms detected in our patients, the intronic rs3730849 of LIG1, the 3`-UTR rs1052536 of LIG3 and the intronic rs3212948 of ERCC1 are associated with a risk of lung cancer (LANDI et al., 2006; MA et al., 2007) . Similarly, the 5`-UTR variant rs1800975 of XPA is associated with lung cancer risk and also with squamous cell carcinoma (Lou et al, 2014) . In GADD45A, an intronic rs532446 was reported to possess a functional role in acute lung injury (MITRA et al., 2014) . The 5`-UTR rs1799943 of BRCA2 is associated with breast cancer susceptibility (SAPKOTA et al., 2013) . The 3`-UTR rs11226 located in RAD52 is reported to has a significant association with myelodysplastic syndrome (BELICKOVA et al., 2013) . The intronic rs1799796 of XRCC3 is associated with ovarian cancer risk (YUAN et al., 2014) , while the intronic rs1805377 of XRCC4 is associated with an increased risk of glioma development (ZHAO et al., 2013) . In addition, the intronic variant rs664677 of ATM may play an important role in the development of thyroid cancer (SONG et al., 2015) while the 3`-UTR rs678653 located in CCND1 is associated with oral cancer (TSAI et al., 2011) . Regarding the intronic rs1805403 of PARP1 as well as the 5`-UTR rs3732974 located in FANCD2, the clinical significance of these substitutions has not yet been elucidated.
Investigation of the relatively large number of SNPs, as in the current report, probably diminishes the significance of findings; therefore, many of the SNPs assessed (e.g. polymorphisms located in ATM, APEX APE 1, XRCC1, ERCC2, MSH3, PARP4, NBS1, BARD1, CDKN1B, TP53, TP53BP1) should be considered as promising candidates for further investigation in larger cohort. In addition, since Fanconi anemia is a genetically heterogeneous disease, the future investigation should also encompass the SNPs located in other genes that are proven to contribute to FA condition i.e., genes involved in bioenergetic pathways, antioxidant activities, response to stress and metal-chelating proteins, inflammation-related cytokines and also in some selected DNA repair genes such as type II DNA topoisomerase (PAGANO et al., 2013) . The present report, although descriptive in its nature, may serve as a source for further studies, which may confirm the use of SNPs as predictive and prognostic biomarkers to individualize therapy of FA patients on genetic basis. Institut za nuklearne nauke Vinča, Univerzitet u Beogradu, Beograd, Srbija 2 Ginekološko akušerska klinika "Narodni front", Beograd, Srbija 3 Medicinski fakultet, Univerzitet u Beogradu, Beograd, Srbija 4 Institut za zdravstvenu zaštitu majke i deteta Srbije "Dr. Vukan Čupić", Beograd, Srbija Izvod Fankonijeva anemija (FA) je genetički heterogeno oboljenje koje se manifestuje progresivnom pancitopenijom, razvojnim abnormalnostima i predispozicijom ka razvoju kancera. Nezavisno od mutacija u FANC genima koje su direktni uzročnici bolesti, identifikacija varijacija u DNK, naročito pojedinačnih nukleotidnih polimorfizama u odabranim genima, može omogućiti individualizaciju pristupa svakom pacijentu i poboljšati prognozu bolesti. U ovom istraživanju, ispitali smo 95 pojedinačnih nukleotidnih izmena lociranih u 52 ključna gena uključena u bazni ekscizioni reper, nukleotidni ekscizioni reper," mismatch" reper, reper dvolančanih prekida DNK, kao i u nekoliko gena odgovornih za kontrolu ćelijskog ciklusa i apoptoze. Istraživanjem su obuhvaćena pet FA-D2 pacijenta i jedan FA-A pacijent, a genotipizacija polimorfizama je izvršena pomoću DNK reper čipa (Asper Biotech). Proučavani su sinonimni (n=10) i nesinonimni ("missense") polimorfizmi (n=52), kao i polimorfizmi u nekodirajućim regionima genoma (introni i 5' i 3' netranslatorni regioni) (n=33). Rezultati našeg istraživanja pokazuju da se pacijenti međusobno razlikuju po tipu i po broju nukleotidnih polimorfizama i istovremeno ukazuju na potrebu daljeg ispitivanja polimorfizama lociranih u genima ATM, APEX APE 1, XRCC1, ERCC2, MSH3, PARP4, NBS1, BARD1, CDKN1B, TP53 and TP53BP,1 na većem broju pacijenata, što bi omogućilo bolji uvid u kliničku sliku bolesti. Pored toga, pokazano je da pojedinačni nukleotidni polimorfizmi mogu imati značajnu ulogu u predikciji kancera kod FA pacijenata, kao i u proceni efikasnosti i toksičnosti različitih vidova terapije.
ISPITIVANJE POJEDINAČNIH NUKLEOTIDNIH
